Biotech company Rigvir Group, who owns a registered oncolytic virotherapy medicine RIGVIR^® is looking for partners globally to support and finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

We have elaborated collaboration model for Rigvir combination with chekpoint inhibitors and registration roadmap for unmet medical needs – early Melanoma and Uveal Melanoma treatment – considering the followin:

• Medical need – currently no treatment solutions for early both Melanoma and Uveal Melanoma;
• Company owns a unique and well-established treatment method;
• Company owns a GMP API production and know-how;
• RIGVIR^® has Excellent safety profile;
• New projects are supported by preclinical data and retrospective clinical observations;
• The production and use of ECHO7 virus RIGVIR^® have granted strong international IP protection;
• The Company has EMA authorization to start any Phase II clinical trials in the EU.

Information Request